Arbutus: Positive Imdusiran Data Leads To Phase 2B Development

Group 1 - Arbutus Biopharma reported positive data from its phase 2a IM-PROVE I trial, utilizing its drug Imdusiran (AB-729) in combination with short courses of pegylated interferon alfa-2a to treat Hepatitis B patients [2] - The combination regimen showed promising results, indicating potential for further development in Hepatitis B treatment [2] Group 2 - The Biotech Analysis Central service offers in-depth analysis of various pharmaceutical companies, including a library of over 600 biotech investing articles and a model portfolio of small and mid-cap stocks [2] - The service is available for $49 per month, with a discounted yearly plan at$399, providing investors with resources to make informed decisions [1]